PharmaShots Connects Brands & Decision-Makers with Custom Media Solutions PharmaShots Provides Curated News & Insights for the Biopharma & Healthcare Industry PharmaShots is Empowering Decision Makers with Actionable Insights Amplify Your Brand with PharmaShots’ Expert Content Creation & Marketing Solutions PharmaShots Enables Brands to Strategically Connect with Their Target Audiences Deliver Your News to the Right Audience with PharmaShots Newswire CXO TALKS CXO TALKSPharmaShots CXO Talks | Women’s History Month Special: A Conversation with Dr. Emanuela Offidani of Tris Pharma CXO TALKSPharmaShots CXO Talks | A Conversation with Liz Benditt, Founder & CEO, The Balm Box CXO TALKSCXO Talks: Vikas Sharma Reveals QurAlis’ Bold Vision for the Future of Neuroscience CXO TALKSCXO Talks: Josh Wittner from Gene By Gene in a Riveting Conversation with PharmaShots EXCLUSIVE INTERVIEW EXCLUSIVEExclusive: A Stimulating Dialogue with Edmund Ben Ami, Co-Founder & CEO of NeuraLight EXCLUSIVEExclusive: Dr. Mónica Domínguez from Smile Train in a Stimulating Conversation with PharmaShots on Why a Healthy Mouth is a Happy Mind EXCLUSIVEExclusive: Kenneth Sake from Blueprint Medicines in an Enlightening Conversation with PharmaShots EXCLUSIVEExclusive Coverage: Dr. Ikshit Sharma from AIMIL Pharmaceuticals in a Stimulating Dialogue Exchange with PharmaShots EXCLUSIVEAdvancing Care for Hematologic Malignancies: Chris Heery from Arcellx in a Stimulating Dialogue Exchange with PharmaShots EXCLUSIVEDecoding Approval: Moitreyee Chatterjee-Kishore from Astellas in an Exclusive Conversation with PharmaShots EXCLUSIVEAdvancing Urothelial Carcinoma Care: Ahsan Arozullah from Astellas Pharma in an Exclusive Interview with PharmaShots EXCLUSIVEExclusive: David Esposito in an Illuminating Discussion with PharmaShots LATEST NEWSStay up-to-date Roche to Acquire PathAI for ~$1.05B 13 minutes ago Angelini Pharma to Acquire Catalyst Pharmaceuticals for ~$4.1B 2 hours ago Siran Bio Inks ~$1B Licensing Deal with GSK for SA030 3 hours ago Artera Secures FDA Clearance for AI-Based Breast Cancer Risk Tool 4 hours ago BriaCell Therapeutics Reports US FDA IND Clearance to Initiate P-I/II Trial of Bria-BRES+ in Breast Cancer 22 hours ago Alebund Pharmaceuticals Completes Patient Enrollment in P-III (RESPOND-2) Trial of AP301 for Hyperphosphatemia 23 hours ago Read More Your Daily Dose of Biopharma News & Insights Delivered to Your Inbox. Join the PharmaShots Family of 20000+ subscribers Subscribe Now
BriaCell Therapeutics Reports US FDA IND Clearance to Initiate P-I/II Trial of Bria-BRES+ in Breast Cancer 22 hours ago
Alebund Pharmaceuticals Completes Patient Enrollment in P-III (RESPOND-2) Trial of AP301 for Hyperphosphatemia 23 hours ago
